Brainstorm Cell Therapeutics (BCLI)
OTHER OTC:BCLI
Want to see BCLI full AI Analyst Report?
Total Valuation
Brainstorm Cell Therapeutics has a market cap or net worth of $7.95M. The enterprise value is $8.98M.
Market Cap$7.95M
Enterprise Value$8.98M
Share Statistics
Brainstorm Cell Therapeutics has 11,034,775 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding11,034,775
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Brainstorm Cell Therapeutics’s return on equity (ROE) is 1.00 and return on invested capital (ROIC) is 96.71%.
Return on Equity (ROE)1.00
Return on Assets (ROA)-14.42
Return on Invested Capital (ROIC)96.71%
Return on Capital Employed (ROCE)0.97
Revenue Per Employee0.00
Profits Per Employee-381.74K
Employee Count27
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Brainstorm Cell Therapeutics is ―. Brainstorm Cell Therapeutics’s PEG ratio is 0.00328.
PE Ratio―
PS Ratio0.00
PB Ratio-0.50
Price to Fair Value-0.50
Price to FCF-0.73
Price to Operating Cash Flow-1.18
PEG Ratio0.00328
Income Statement
In the last 12 months, Brainstorm Cell Therapeutics had revenue of 0.00 and earned -10.31M in profits. Earnings per share was -1.11.
Revenue0.00
Gross Profit0.00
Operating Income-9.95M
Pretax Income-10.31M
Net Income-10.31M
EBITDA-9.75M
Earnings Per Share (EPS)-1.11
Cash Flow
In the last 12 months, operating cash flow was -6.66M and capital expenditures 0.00, giving a free cash flow of -6.66M billion.
Operating Cash Flow-6.66M
Free Cash Flow-6.66M
Free Cash Flow per Share-0.60
Dividends & Yields
Brainstorm Cell Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.33
52-Week Price Change-33.98%
50-Day Moving Average0.80
200-Day Moving Average0.68
Relative Strength Index (RSI)46.74
Average Volume (3m)22.93K
Important Dates
Brainstorm Cell Therapeutics upcoming earnings date is Aug 17, 2026, Before Open (Confirmed).
Last Earnings DateMay 15, 2026
Next Earnings DateAug 17, 2026
Ex-Dividend Date―
Financial Position
Brainstorm Cell Therapeutics as a current ratio of 0.03, with Debt / Equity ratio of -13.52%
Current Ratio0.03
Quick Ratio0.03
Debt to Market Cap0.04
Net Debt to EBITDA-0.02
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Brainstorm Cell Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Brainstorm Cell Therapeutics EV to EBITDA ratio is -0.54, with an EV/FCF ratio of -0.76.
EV to Sales0.00
EV to EBITDA-0.54
EV to Free Cash Flow-0.76
EV to Operating Cash Flow-0.76
Balance Sheet
Brainstorm Cell Therapeutics has $15.00K in cash and marketable securities with $1.49M in debt, giving a net cash position of -$1.47M billion.
Cash & Marketable Securities$15.00K
Total Debt$1.49M
Net Cash-$1.47M
Net Cash Per Share-$0.13
Tangible Book Value Per Share-$1.11
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Brainstorm Cell Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast52.48%